Clinical trials · Minneapolis–St. Paul, MN
Metastatic Malignant Neoplasm in the Brain clinical trials in Minneapolis–St. Paul
We’re tracking 7 recruiting metastatic malignant neoplasm in the brain studies with a site in or near Minneapolis–St. Paul — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Minneapolis–St. Paul
- NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Minneapolis, MinnesotaAges 18 years+ - NCT04511013RecruitingPhase 2
Trial for BRAF-mutant melanoma spread to the brain
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Minneapolis, MinnesotaAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Minneapolis, MinnesotaAges 1–21 - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Minneapolis, MinnesotaAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07227415RecruitingPhase 1/Phase 2
Study of a new drug for advanced kidney cancer
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Edina, MinnesotaAges 18 years+
Hear when a new Metastatic Malignant Neoplasm in the Brain trial opens near Minneapolis–St. Paul, MN
We’ll email you when one opens near Minneapolis–St. Paul, MN — at most once a week, no account needed, unsubscribe anytime.
Metastatic Malignant Neoplasm in the Brain trials in other cities
Where these studies are running near Minneapolis–St. Paul
Institutions with a site for the recruiting metastatic malignant neoplasm in the brain studies listed above.
- Minnesota Oncology Hematology PA-Maplewood · 3 studies
- Minnesota Oncology Hematology PA-Woodbury · 3 studies
- Abbott-Northwestern Hospital · 2 studies
- Cancer Center of Western Wisconsin · 2 studies
- Fairview Clinics and Surgery Center Maple Grove · 2 studies
- Fairview Lakes Medical Center · 2 studies
- Fairview Southdale Hospital · 2 studies
- Health Partners Inc · 2 studies
What taking part in a metastatic malignant neoplasm in the brain study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic malignant neoplasm in the brain studies in Minnesota.
Common questions
- Are there metastatic malignant neoplasm in the brain clinical trials near Minneapolis–St. Paul?
- Yes. We're currently tracking 7 recruiting metastatic malignant neoplasm in the brain studies with a site near Minneapolis–St. Paul, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic malignant neoplasm in the brain study near Minneapolis–St. Paul?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minneapolis–St. Paul to take part?
- Not necessarily. These studies have a site near Minneapolis–St. Paul, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic malignant neoplasm in the brain trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic malignant neoplasm in the brain studies open near Minneapolis–St. Paul regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.